Last reviewed · How we verify
anti-MUC1 CAR T Cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
anti-MUC1 CAR T Cells (anti-MUC1 CAR T Cells) — PersonGen BioTherapeutics (Suzhou) Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti-MUC1 CAR T Cells TARGET | anti-MUC1 CAR T Cells | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti-MUC1 CAR T Cells CI watch — RSS
- anti-MUC1 CAR T Cells CI watch — Atom
- anti-MUC1 CAR T Cells CI watch — JSON
- anti-MUC1 CAR T Cells alone — RSS
Cite this brief
Drug Landscape (2026). anti-MUC1 CAR T Cells — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-muc1-car-t-cells. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab